Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP12146 in Locally Advanced or Metastatic Solid Tumors
NCT05002868Phase 1Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of rp12146 in solid tumor, small cell lung cancer (SCLC), breast cancer and 9 more, sponsored by Rhizen Pharmaceuticals AG. Primary endpoints: Maximum Tolerated Dose at 28 days and Treatment-Emergent Adverse Events at 2 years. Started Oct 2021; status: completed.
02
Drugs
rp12146
03
Conditions
solid tumorsmall cell lung cancer (SCLC)breast cancerovarian cancerfallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT05002868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002868.